SDGR Schrödinger, Inc.

Schrödinger (SDGR) has drawn fresh attention after recent trading left the share price at US$28.85, with the stock up strongly over the past month and past 3 months. Investors are reassessing what that move reflects. For context, Schrödinger’s recent surge sits on top of a 30-day share price return of 46.45% and a 90-day share price gain of 65.90%. At the same time, the 1-year total shareholder return of 49.48% contrasts with a 5-year total shareholder loss of 46.56%, signalling powerful...

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

Schrodinger (SDGR) is trading at new 2-year highs. SDGR maintains strong technical momentum with shares up more than 50% over the past year. SDGR maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed, with price targets from $17 to $41.17 and high short interest (15.02%). Caution is...

The low purchase price of Helomics and low revenue suggest that the acquisition is not that promising for DataMEDS AI.

SOPHiA GENETICS (SOPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.

AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines.

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.

In the past few days, Schrödinger, Inc. reported second-quarter 2026 results showing revenue of US$58.89 million and a shift to a US$5.98 million net profit, while also expanding its long-running collaboration with Bristol Myers Squibb to deploy its new agentic AI co-scientist, Bunsen, across that partner’s research organization. Alongside this earnings turnaround, Schrödinger’s AI agreement with Bristol Myers Squibb and the related ESOP shelf registration highlight both growing adoption of...

Schrodinger Inc (SDGR) reports robust Q2 2026 with record ACV growth, strategic AI advancements, and raised full-year drug discovery guidance despite margin pressures from hosted transition.

Schrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter

Schrodinger (SDGR) delivered earnings and revenue surprises of +113.33% and +15.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?